Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC) by Allen, Naomi E et al.
Endogenous sex hormones and
endometrial cancer risk in women in the
European Prospective Investigation into
Cancer and Nutrition (EPIC)
Naomi E Allen, Timothy J Key, Laure Dossus
14, Sabina Rinaldi
1, Anne Cust
1,2,
Annekatrin Lukanova
14, Petra H Peeters
3, N Charlotte Onland-Moret
3,
Petra H Lahmann
4, Franco Berrino
5, Salvatore Panico
6, Nerea Larran ˜aga
7,
Guillem Pera
8, Maria-Jose ´ Tormo
9, Maria-Jose ´ Sa ´nchez
10,JR a m o ´nQ u i r o ´s
11,
Eva Ardanaz
12, Anne Tjønneland
13, Anja Olsen
13, Jenny Chang-Claude
14,
Jakob Linseisen
14, Mandy Schulz
15, Heiner Boeing
15, Eva Lundin
16,
Domenico Palli
17, Kim Overvad
18,F r a n c ¸oise Clavel-Chapelon
19, Marie-
Christine Boutron-Ruault
19, Sheila Bingham
20, Kay-Tee Khaw
21,
H Bas Bueno-de-Mesquita
22, Antonia Trichopoulou
23, Dimitiros Trichopoulos
23,
Androniki Naska
23, Rosario Tumino
24, Elio Riboli
25 and Rudolf Kaaks
14
Cancer Research UK Epidemiology Unit, University of Oxford, Oxford, UK
1Nutrition and Hormones Group, International Agency for Research on Cancer, Lyon, France
2University of Sydney, Sydney, Australia and University of Lyon, Lyon, France
3Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
4Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, UK
5Epidemiology Unit, Istituto Tumori, Milan, Italy
6Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
7Public Health Department of Gipuzkoa, Basque Government, San Sebastian, Spain
8Department of Epidemiology, Catalan Institute of Oncology (ICO), Barcelona, Spain
9Consejerı ´a de Sanidad y Polı ´tica Social, Murcia, Spain
10Andalusian School of Public Health, Granada, Spain
11Public Health & Health Planning Directorate, Asturias, Spain
12Instituto de Salud Pu ´blica de Navarra, Pamplona, Spain
13Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
14Division of Cancer Epidemiology, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
15German Institute of Human Nutrition, Potsdam-Rehbu ¨cke, Germany
16Department of Nutritional Research, University of Umea ˚, Umea ˚, Sweden
17Molecular and Nutritional Epidemiology Unit, CSPO-Scientiﬁc Institute of Tuscany, Florence, Italy
18Department of Clinical Epidemiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
19Inserm E3N-EPIC, Institute Gustave Roussy, Villejuif, France
20MRC Dunn Human Nutrition Unit, University of Cambridge, Cambridge, UK
21Clinical Gerontology Unit, Addenbrooke’s Hospital, Cambridge, UK
22National Institute of Public Health and the Environment, Center for Nutrition and Health, Bilthoven, The Netherlands
23Department of Hygiene and Epidemiology, School of Medicine, University of Athens, Athens, Greece
24Cancer Registry, Azienda Ospedaliera ‘Civile M P Arezzo’, Ragusa, Italy
25Cancer Epidemiology and Prevention, Department of Epidemiology and Public Health, Faculty of Medicine, Imperial College
London, London, UK
(Correspondence should be addressed to R Kaaks; Email: r.kaaks@dkfz.de)
Abstract
Epidemiological data show that reproductive and hormonal factors are involved in the etiology of
endometrial cancer, but there is little data on the association with endogenous sex hormone
levels. We analyzed the association between prediagnostic serum concentrations of sex steroids
and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition
using a nested case–control design of 247 incident endometrial cancer cases and 481 controls,
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premenopausal women, phase of menstrual cycle. Using conditional regression analysis,
endometrial cancer risk among postmenopausal women was positively associated with increasing
levels of total testosterone, free testosterone, estrone, total estradiol, and free estradiol.
The odds ratios (ORs) for the highest versus lowest tertile were 2.66 (95% conﬁdence interval
(CI) 1.50–4.72; PZ0.002 for a continuous linear trend) for estrone, 2.07 (95% CI 1.20–3.60;
PZ0.001) for estradiol, and 1.66 (95% CI 0.98–2.82; PZ0.001) for free estradiol. For total and
free testosterone, ORs for the highest versus lowest tertile were 1.44 (95% CI 0.88–2.36;
PZ0.05) and 2.05 (95% CI 1.23–3.42; PZ0.005) respectively. Androstenedione and
dehydroepiandrosterone sulfate were not associated with risk. Sex hormone-binding globulin
was signiﬁcantly inversely associated with risk (OR for the highest versus lowest tertile was 0.57,
95% CI 0.34–0.95; PZ0.004). In premenopausal women, serum sex hormone concentrations
were not clearly associated with endometrial cancer risk, but numbers were too small to draw ﬁrm
conclusions. In conclusion, relatively high blood concentrations of estrogens and free testosterone
are associated with an increased endometrial cancer risk in postmenopausal women.
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Introduction
Endometrial cancer comprises about 4% of all cancers
in women worldwide (Parkin et al. 2002) and is the
fourth most common cancer in women in westernized
countries (Parkin et al. 2002, Bray et al. 2005). Obesity
is an important risk factor for this disease in both pre-
and postmenopausal women, accounting for w 40% of
the incidence (Bergstrom et al. 2001). The physiologi-
cal mechanisms underlying this relationship are not
completely understood, but may involve alterations in
endogenoussexsteroidmetabolism(Kaaksetal.2002).
The predominant hypothesis describing the relation-
ship between sex steroid hormones and endometrial
cancer risk is known as the ‘unopposed estrogen’
hypothesis (Henderson et al.1 9 8 2 , Key & Pike 1988).
The ‘unopposed estrogen’ hypothesis states that endo-
metrialcancerriskisincreasedamongwomenwhohave
high circulating levels of bioavailable estrogens and low
levels of progesterone, so that the mitogenic effect of
estrogens is insufﬁciently counterbalanced by the
opposing effect of progesterone (Henderson et al.1 9 8 2 ,
Key&Pike1988).Theunopposedestrogenhypothesisis
supported by the observations that the use of estrogen-
only hormone-replacement therapy (HRT; Beral et al.
2005) and sequential oral contraceptives (OCs; Weiss &
Sayvetz 1980) greatly increase endometrial cancer risk,
while combined preparations of OCs and HRT (i.e., that
contain progestagen as well as estrogen throughout the
treatment period) have a protective effect (Cancer and
Steroid Hormone Study 1987, Beral et al.2 0 0 5 ).
Most of the larger retrospective case–control studies
(with 50 or more cases) have shown that blood levels of
estrogens are higher in postmenopausal women with
endometrial cancer than in healthy control subjects
(Austinetal.1991,Nyholmetal.1993,Potischmanetal.
1996).Inpremenopausalwomen,dataontheassociation
between circulating levels of sex steroid hormones and
endometrial cancer risk are sparse, but suggest a role for
elevated levels of estrone and androstenedione
(Potischman et al.1 9 9 6 ). To date, only two prospective
studies have examined the relationship of endometrial
cancer risk with prediagnostic circulating levels of sex
steroids, and these studies focused entirely on women
who were postmenopausal at the time of blood donation
(Zeleniuch-Jacquotte et al.2 0 0 1 , Lukanova et al.2 0 0 4 ).
We report here the results from a case–control study
nested within the European Prospective Investigation
into Cancer and Nutrition (EPIC), in which we
examined the relationship between prediagnostic
serum concentrations of sex steroids and endometrial
cancer risk among pre- and postmenopausal women. In
addition, we examined whether sex hormones might
explain the association between obesity and risk. With
a total of 247 incident cases of endometrial cancer and
481 matched controls, this is the largest prospective
study to date on the relationships between endometrial
cancer risk and serum levels of estrogens, androgens,
and sex hormone-binding globulin (SHBG).
Subjects and methods
Study cohort
EPIC recruitment procedures and collection of ques-
tionnaire data, anthropometric measurements, and
blood samples have been described in detail previously
(Riboli et al. 2002). In brief, extensive standardized
questionnaire data on dietary and non-dietary variables
were collected between 1992 and 1998 from about
500 000 individuals across Europe, and a blood sample
was collected from about 400 000 individuals.
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occurring after blood collection and matched control
subjects from eight of the ten participating countries:
Denmark, France, Germany, Greece, Italy, the Nether-
lands, Spain, and the United Kingdom. Norway was
not included in the present study because blood
samples have been collected only recently and very
few cases of endometrial cancer have been diagnosed.
Sweden was not included because of limited ques-
tionnaire information at the time of blood donation
about menopausal status, past and current use of
exogenous hormones, and phase of menstrual cycle
(Malmo ¨), and because endometrial cancer case patients
had already been included in a previous study (Umea ˚;
Lukanova et al. 2004).
A 30 ml blood sample was collected according to
a standardized protocol. Filled syringes were kept at
5–10 8C, protected from light, and transferred to a local
laboratory for further processing and aliquoting, with
the exception of subjects recruited through the Oxford
center. Here, blood samples were collected throughout
the United Kingdom and transported to a laboratory in
Norfolk by mail at ambient temperature. (The stability
of serum sex steroid levels measured in blood
transported at ambient temperatures or kept at ambient
temperatures for 24 or 48 h has been documented
previously (Hankinson et al. 1989, Murphy et al.
2000)). Blood fractions (serum, plasma, red cells, and
buffy coat for DNA extraction) were aliquoted into
0.5 ml straws, which were then heat sealed and stored
in liquid nitrogen tanks at K196 8C, except in
Denmark where samples were stored in 1 ml tubes in
nitrogen vapor at K150 8C.
Determination of menopausal status
Women were considered premenopausal at the time of
blood donation when they reported having had regular
mensesoverthepast12months,orwhentheywere!42
years of age, because 99.5% of EPIC women who had
complete data were premenopausal below age 42.
Women were considered postmenopausal when they
reported not having had any menses over the past 12
months or when they reported a bilateral ovariectomy.
Women who had incomplete data were considered
postmenopausal when they were older than 55 years.
Women who were between 42 and 55 years of age
(inclusive) and had equivocal questionnaire data for
menopausalstatuswereclassiﬁedashavinganunknown
menopausal status and were excluded from the sub-
sequent analyses. Women who had had a hysterectomy
were also excluded from the study. The methods used to
determinethephaseofmenstrualcycleatblooddonation
from premenopausal women have been described in
detail previously (Kaaks et al.2 0 0 5 ).
Follow-up for cancer incidence and vital status
In Denmark, Italy, the Netherlands, Spain, and the
United Kingdom, incident cancer cases were identiﬁed
through record linkage with regional cancer registries.
In France, Germany, and Greece, follow-up was based
on a combination of methods, including health
insurance records, cancer, and pathology registries,
and active follow-up through study subjects and their
next of kin. Data on vital status in most EPIC study
centers were collected from mortality registries at the
regional or national level, in combination with data
collected by active follow-up (Greece). For each EPIC
study center, closure dates of the study period were
deﬁned as the latest dates of complete follow-up for
both cancer incidence and vital status (dates varied
between centers, from June 1999 to December 2003).
Selection of case and control subjects
Case subjects were women who developed endometrial
cancer after the date of blood donation and before the
end of the study period, deﬁned for each study center
by the latest date of follow-up. Case and control
subjects were selected among women who had no
previous diagnosis of cancer (except non-melanoma
skin cancer) and were not currently using exogenous
hormones at the time of blood donation. Among past
HRT users, no information was available on the type or
duration of HRT use.
In total, the eight sub-cohorts contributing to the
present study included 135 953 women who were not
taking exogenous hormones at the time of blood
donation, of whom 301 had a diagnosis of endometrial
cancer by the end of each center’s follow-up period.
After excluding cases with insufﬁcient sera (nZ8) or
who had an unknown menopausal status (nZ46),
matched control subjects were identiﬁed for 247 cases.
These included 54 cases in Denmark, 52 in Italy, 37 in
Spain, 28 in the Netherlands, 32 in the UK, 20 in
Germany, 16 in France, and 8 in Greece. Detailed
tumor morphology was speciﬁed for 127 cases (51%),
of which 118 cases (94%) were classiﬁed as type I
(endometrioid adenocarcinomas) and 9 cases (6%) as
type II (serous papillary, clear cell or squamous
adenocarcinomas; Tavassoli & Devilee 2003).
For each case subject, up to two control subjects were
chosenatrandom among appropriate risksetsconsisting
of all cohort members alive and free of cancer (except
non-melanomaskincancer)atthetimeofdiagnosisofthe
index case. An incidence density sampling protocol for
control selection was used, such that control subjects
Endocrine-Related Cancer (2008) 15 485–497
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whileeachcontrolcouldalsobesampledmorethanonce.
Matching criteria included: study center, menopausal
status (premenopausal, postmenopausal), age at enroll-
ment (G6 months), time of the day of blood collection
(G1 h), and, for premenopausal women, phase of
menstrual cycle (‘early follicular’ (days 0–7 of the
cycle),‘latefollicular’(days8–11),‘periovulatory’(days
12–16),‘midluteal’(days20–24),and‘otherluteal’(days
17–19 or 25–40)). Case patients and control subjects
were also matched on time between blood draw and last
consumptionoffoodsordrinks(!3,3–6,O6 h),inview
offurtherstudiesinwhichendometrialcancerriskwillbe
related to endogenous insulin levels. All participants
gave written consent for future analyses of their blood
samples and the study was approved by the local ethics
committeesintheparticipatingcountriesandtheInternal
Review Board of the IARC.
Hormone assays
Serum testosterone, dehydroepiandrosterone sulfate
(DHEAS), androstenedione (A-dione), and SHBG
levels were measured for all study subjects; serum
estradiol and estrone levels were measured only in
postmenopausal women because of its large intra-
individual variation during the menstrual cycle among
premenopausal women. Serum testosterone and
DHEAS concentrations were measured by radio
immunoassays (Immunotech, Marseilles, France).
A-dione, estradiol, and estrone concentrations were
measured by a radio immunoassay with a double-
antibody system for the separation of free and bound
antigen (Diagnostic Systems Laboratories Inc., Web-
ster, TX, USA). Assays were performed in batches of
76 serum samples, analyzed together on the same day
and with the same immunoassay kit. Serum samples of
case and control subjects that were matched together
were systematically analyzed within the same batch.
SHBG was measured by a solid phase ‘sandwich’
IRMA (Cis-Bio International, Gif-sur-Yvette, France).
Mean intra-batch coefﬁcients of variation (CV) were
estimated to be 5.5% (at 0.54 mmol/l) for DHEAS,
6.6% (at 1.4 nmol/l) for testosterone, 3.0% (at
3.5 nmol/l) for A-dione, 7.4% (at 55.4 pmol/l) for
estrone, 8.4% (at 294 pmol/l) for estradiol, and 3.9%
(at 30 nmol/l) for SHBG. Inter-batch CVs were 14%
for DHEAS, 12% for testosterone, 8.4% for A-dione,
16% for estrone, 20% for estradiol, and 11% for
SHBG. All hormone assays were performed by the
laboratory of the Hormones and Cancer Team at IARC.
The laboratory personnel performing the hormone
assays were blinded as to the case–control status of the
study subjects. Serum concentrations of free testoster-
one and free estradiol, unbound to SHBG or albumin,
were calculated from the absolute concentrations of
each of the steroids and SHBG using mass action
equations, and assuming a constant serum albumin
concentration of 43 g/l (Rinaldi et al. 2002).
Statistical analyses
Inallanalyses,levelsofSHBGandsexsteroidswerelog
transformed to normalize their distributions.
Differences in baseline characteristics between case
patients and control subjects were compared using the
paired t-test for continuous variables and the c
2-test for
categorical variables. The statistical signiﬁcance of
case–control differences in geometric mean hormone
concentrations were evaluated by paired comparisons
(t-tests) of case values versus the average of the two
matched control subjects in each case–control set
(Rosner 1982). Pearson’s partial correlation coefﬁ-
cients, adjusted for age, case–control status, and
laboratory batch were calculated to assess the corre-
lations between hormones and anthropometric indices.
Analysis of covariance was used to investigate
geometric mean differences in hormone levels by the
following variables: country (Denmark, Italy, Spain,
the Netherlands, UK, Germany, France, Greece); OC
use (never, past); HRT use (never, past); smoking
(never,past,current); body massindex(BMI; kg/m
2;i n
quartiles); ever hadafull-term pregnancy (no, yes),and
inpremenopausalwomen,phaseofmenstrualcyclethat
blood was taken (early follicular, late follicular,
periovulatory, midluteal, other luteal), after adjusting
forage (continuous variable),case–control status (case,
control), and laboratory batch (categorical variable).
Relative risks (odds ratios (ORs)) for endometrial
cancer in relation to serum hormone levels were
calculated by conditional logistic regression models,
using the PHREG procedure of the SAS software
package (Version 9). Hormone levels were categorized
intothirdsforpostmenopausalwomentoallowadequate
numbers of subjects in each category. Cut points were
based on the distribution of the hormones among the
control subjects from all EPIC centers combined.
Likelihood ratio tests were used to assess linear trends
in ORs across the categories using the median hormone
values for each category as the quantitative score of
exposureandonacontinuousscale.The95%conﬁdence
intervals (CIs) were computed using the standard errors
of the pertinent regression coefﬁcients.
The effects of additional potential confounders
(other than the matching criteria, controlled for by
design) were examined by including additional
N E Allen et al.: Sex steroids and endometrial cancer risk in EPIC
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Potential confounders included: BMI (continuous
variable), age at menarche (continuous variable), age
at menopause (continuous variable), previous use of
OCs (yes, no), previous use of HRT (yes, no), smoking
(never, past, current), and physical activity (inactive,
moderately inactive, moderately active, active). For all
confounding variables considered in our analyses, the
percentage of missing values was below 3% (except for
age at menopause: 7%). To avoid exclusion of all of
these women from our logistic regression analyses, we
imputed missing values using a sequence of regression
models as describe in Raghunathan et al. (2001). In this
approach, normal linear regression models are used for
continuous variables and polytomous regression
models for categorical variables. All the models
included age at blood donation, study center, and
case–control status as regressors.
The effects of mutual adjustments between estrogens
and testosterone were examined on a continuous scale.
c
2-tests were used to examine heterogeneity of endo-
metrial cancer risk associated with a doubling of
hormone level by study country (eight countries), HRT
use(never,former),andlagtimebetweenblooddonation
and diagnosis (!2y e a r s ,2 C years). Absolute risks of
developing endometrialcancerovera 10-year follow-up
period were calculated using the method described by
Gail et al.( 1 9 8 9 ) . These calculations were performed
forwomeninfourdifferentagecategories(!55,55–59,
60–64, and R65 years) and the age-speciﬁc hazard of
dyingfromothercausesthanendometrialcancerwereset
at 1.7!10
K3,2 . 8 !10
K3,4 . 3 !10
K3, and 4.5!10
K3
respectively for each of these age four groups.
Results
This study includes 247 case patients diagnosed from
recruitment until the end offollow-up: 55 women were
premenopausal at recruitment and 192 were postme-
nopausal. The median age at recruitment was 49 years
(5–95% rangeZ40–54 years) in premenopausal
women and 60 years (5–95% rangeZ53–70 years) in
postmenopausal women. Among cases, the median
time between recruitment and cancer diagnosis was 3.5
years (5–95% rangeZ0.3–7.3 years) for premenopau-
sal women and 3.2 years (5–95% rangeZ0.4–7.0
years) for postmenopausal women. The median age at
cancer diagnosis was 52 years (5–95% rangeZ42–58
years) among women who were premenopausal at
recruitment and 63 years (5–95% rangeZ55–74 years)
among postmenopausal women.
Basic characteristics of the study participants are
shown in Table 1. Overall, case patients were
signiﬁcantly heavier and had a higher BMI than
control subjects, although this difference was found
only in postmenopausal women. Case patients had a
higher age at menopause and were more likely to be
nulliparous, to have never used OCs and previously
used HRT (Table 1). There were no signiﬁcant
differences in height, physical activity, age at
menarche, age at ﬁrst pregnancy, number of pregnan-
cies, smoking, or self-reported prevalence of diabetes
between case patients and control subjects.
Differences in hormone levels according to baseline
characteristics were evaluated after adjusting for age at
blood collection, case–control status, and laboratory
batch. Smoking, past HRT use, OC use, and parity
were not signiﬁcantly associated with serum hormone
levels in all women combined, or in pre- or
postmenopausal women separately (data not shown).
There was no systematic variation over the menstrual
cycle for testosterone, free testosterone, SHBG,
DHEAS, or A-dione.
Pearson partial correlation coefﬁcients between sex
hormones, adjusted for age, case–control status, and
laboratory batch, showed that all the androgens were
positively correlated with each other (Table 2). In
postmenopausal women, androgens were also positively
correlated with estrone, estradiol, and free estradiol. As
expected, SHBG was strongly inversely correlated with
free estradiol and free testosterone. BMI was also
inversely correlated with SHBG (rZK0.42 and K0.43
in pre-and postmenopausalwomen respectively)and,in
turn,positivelycorrelatedwithfreetestosterone(rZ0.38
and 0.23) and free estradiol (rZ0.41 in postmenopausal
women).However,BMIwasnotcorrelatedwithA-dione
or DHEAS in pre- or postmenopausal women.
In women who were premenopausal at the time of
blood donation, there were no signiﬁcant differences in
the geometric mean concentrations of SHBG or
androgens between the 55 case patients and 107 control
subjects (Table 3). In women who were postmenopausal
atthetimeofblooddonation,thegeometricmeanSHBG
concentration was 11% lower among case patients than
in control subjects (PZ0.004; Table 3). Circulating
mean concentrations of total testosterone, free testoster-
one, estrone, estradiol, and free estradiol were 10–18%
higher in case patients than in control subjects (P%0.05
for each hormone). Logistic regression analyses also
showed strong associations between circulating serum
concentrations of these sex hormones and endometrial
cancer risk. A continuous linear trend test showed
increases in endometrial cancer risk with decreasing
levels of SHBG (PtrendZ0.004); when categorized into
thirds, the OR for the highest versus lowest tertile was
0.57 (95% CIZ0.34–0.95; PtrendZ0.03). By contrast,
Endocrine-Related Cancer (2008) 15 485–497
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risk with increasing serum concentrations of total
testosterone and free testosterone (PtrendZ0.05 for
testosterone, and PtrendZ0.005 for free testosterone as
continuous variables),althoughthe relativeriskestimate
for the highest versus lowest tertile was signiﬁcant only
for free testosterone (ORZ2.05; 95% CIZ1.23–3.42;
PtrendZ0.005),andnotfortotaltestosterone(ORZ1.44;
95% CIZ0.88–2.36; PtrendZ0.14). Endometrial cancer
riskwasalsodirectlylinearlyrelatedtocirculatinglevels
ofestrone(PtrendZ0.002),totalestradiol(PtrendZ0.001),
andfreeestradiol(PtrendZ0.001).Whencategorizedinto
thirds,ORsforthehighestversuslowesttertilewere2.66
(95% CIZ1.50–4.72; PtrendZ0.01) for estrone, 2.07
(95% CIZ1.20–3.60; PtrendZ0.01) for estradiol, and
1.66 (95% CIZ0.98–2.82; PtrendZ0.05) for free estra-
diol(Fig.1).Inthisstudypopulation,theabsoluteriskof
developing endometrial cancer for a postmenopausal
women aged 60 years and followed up for 10 years was
estimatedat0.9%forthoseinthehighesttertileofserum
estradiol and 0.5% for those in the lowest tertile. Similar
absolute risks were found for estrone, free estradiol, and
free testosterone (datanot shown). A-dione and DHEAS
had similar mean serum levels among postmenopausal
case patients and control subjects and showed no
association with endometrial cancer risk in logistic
regression analyses.
BMI was signiﬁcantly associated with endometrial
cancer risk among postmenopausal women; com-
pared with women of a normal BMI (!25 kg/m
2),
the ORs associated with being overweight (BMI
25–29 kg/m
2) and obese (BMI 30C kg/m
2)
were 1.26 (95% CIZ0.81–1.96) and 2.67 (95% CIZ
1.63–4.37; PtrendZ0.0001) respectively. The associ-
ation between BMI and endometrial cancer risk was
moderately attenuated after adjusting for free estradiol;
the risk associated with being obese compared with
women of a normal BMI was reduced from 2.67 to 2.09
(95% CIZ1.22–3.57; PtrendZ0.009) and the corre-
sponding c
2-value declined by halffrom 15.23 to 7.24;
Table 1 Basic characteristics of endometrial cancer patients and control subjects: median (5th–95th percentile), unless otherwise
stated
Cases Controls P for difference
a
Number 247 481
Menopausal status
Premenopausal 55 107
Postmenopausal 192 374
Age at blood donation 58.4 (45.0–68.8) 58.4 (44.9–68.6) 0.48
Age at diagnosis 61.0 (47.0–72.0) – –
Height (m) 160.0 (149.0–171.0) 160.0 (149.5–171.0) 0.48
Weight (kg) 68.6 (52.8–96.0) 67.5 (51.6–88.5) 0.0002
BMI (kg/m
2) All women 27.4 (21.1–37.4) 26.0 (20.2–34.8) 0.0001
Premenopausal 25.2 (20.4–36.5) 25.4 (19.5–33.6) 0.53
Postmenopausal 27.7 (21.4–37.9) 26.1 (20.6–35.5) 0.0001
Age at menarche 13.0 (11.0–15.0) 13.0 (11.0–16.0) 0.17
Nulliparous (%) 20.7 9.6 !0.0001
Number of pregnancies
b 2.0 (1.0–4.0) 2.0 (1.0–5.0) 0.16
Age at ﬁrst pregnancy
b 24.5 (18.0–31.0) 25.0 (19.0–34.0) 0.40
Age at menopause
c 52.0 (45.0–56.0) 50.0 (41.0–55.0) 0.0004
Previous OC use (%) 32.4 39.5 0.03
Previous HRT use (%) 20.2 13.3 0.02
Diabetes (%) 4.1 4.2 0.90
Physical activity (%)
Inactive 11.7 9.2 0.30
Moderately inactive 27.9 23.9
Moderately active 49.4 57.0
Active 10.1 9.8
Unknown 0.8 0.2
Smoking status (%)
Never smoker 66.8 60.7 0.29
Ex smoker 19.0 21.6
Current smoker 13.8 16.8
Unknown 0.4 0.8
aTwo-sided paired t-test for continuous variables and c
2-test for categorical variables.
bAmong parous women only.
cAmong postmenopausal women only.
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albeit slightly weaker effects on the association
between BMI and cancer risk. Adjustment for free
testosterone or the other androgens did not appreciably
alter the association between BMI and cancer risk in
postmenopausal women (data not shown).
In turn, the associations between sex hormones and
endometrial cancer risk were somewhat attenuated after
adjustment for BMI, although the association
with estrone remained statistically signiﬁcant (OR
for the highest versus lowest tertileZ2.19 (95%
CIZ1.21–3.97; PtrendZ0.01; Fig. 2). The association
for free testosterone with risk was attenuated further
after adjustment for BMI, although it remained
statistically signiﬁcant(OR for the highest versuslowest
tertileZ1.74 (95% CIZ1.02–2.96; PtrendZ0.04).
Adjustment for BMI had a negligible effect on the
association between total testosterone and endometrial
cancer risk, although it weakened the association with
SHBG, estradiol, and free estradiol, which were no
longer statistically signiﬁcant (Fig. 2). Further adjust-
ments for age at menarche, parity, age at menopause,
smoking, and physical activity made little difference to
these ﬁndings (data not shown).
After adjustment for estrone and estradiol levels, the
effect on endometrial cancer risk associated with a
doubling of testosterone and free testosterone concen-
tration was strongly attenuated, and no longer
statistically signiﬁcant (from 30 to 6% increased
risk for testosterone and from 40 to 19% for
free testosterone). The strength of the association
with estrogens was also reduced after adjustment
for testosterone levels but the models remained
statistically signiﬁcant. (The OR for a doubling of
estrogen levels decreased from 2.02 (PtrendZ0.0002)
to 1.79 (PtrendZ0.02) for estrone and from 2.29
(PtrendZ0.001) to 2.16 (PtrendZ0.02) for estradiol).
We next examined whether the associations between
sex hormones and endometrial cancer risk varied
according to the time between blood draw and cancer
diagnosis in postmenopausal women. There was some
evidence of heterogeneity in risk associated with a
doubling of hormone concentration for case patients
diagnosed !2 years since blood collection compared
with cases diagnosed more than 2 years for most
hormones, and which was statistically signiﬁcant for
estradiol(c
2Z8.3;PheterogeneityZ0.004)andtestosterone
(c
2Z5.2; PheterogeneityZ0.02). Overall, restricting the
analyses to 134 postmenopausal women diagnosed at
least 2 years after blood collection strengthened the
associations between sex hormones and endometrial
cancer risk; ORs for the highest versus lowest tertile
of estrone, estradiol, and free estradiol were 4.17
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www.endocrinology-journals.org 491(95% CIZ1.98–8.80; Ptrend!0.0001), 3.19 (95%
CIZ1.61–6.32; Ptrend!0.0001) and 2.05 (95% CIZ
1.09–3.87; Ptrend!0.0001) respectively. The association
between testosterone and free testosterone was also
strengthened with ORs for the highest versus lowest
tertile of 1.94 (95% CIZ1.09–3.45; PtrendZ0.01) for
testosterone and 2.34 (95% CIZ1.30–4.22; PtrendZ
0.002) for free testosterone. Restricting the analysis to
case patients diagnosed 1 year after blood collection
produced similar results, although the tests for hetero-
geneity were not statistically signiﬁcant (data not
shown).
When the analyses were restricted to postmenopau-
sal women who never used HRT in the past, the
association between estrone levels and endometrial
cancer risk was strengthened (OR for the highest
versus lowest tertile Z3.68; 95% CIZ1.79–7.58;
Ptrend!0.0001). However, there was no evidence of
heterogeneity of the association of hormones with
endometrial cancer risk between past and never users
of HRT or between the participating countries. Further,
the results were similar when based on center-speciﬁc
cut points instead of the cut points determined on the
control subjects from all study centers combined (data
not shown).
Discussion
This prospective study shows that circulating blood
levels of estrogens and testosterone are positively
associated with an increased risk of endometrial cancer
in postmenopausal women. These results were statisti-
cally signiﬁcant, similar between the eight European
countries included in the analysis, and not altered by
smoking, parity, and other known risk factors for
endometrial cancer. These ﬁndings are consistent with
data from two smaller prospective studies (that included
124 (Lukanova et al.2 0 0 4 ) and 57 postmenopausal
cases (Zeleniuch-Jacquotte et al.2 0 0 1 )r e s p e c t i v e l y )
and most of the larger case–control studies that have
analyzedsexhormonelevelsinblood(Austinetal.1991,
Nyholm et al.1 9 9 3 , Potischman et al.1 9 9 6 )o ru r i n e
(Baanders-vanHalewijn&Poortman1985)inrelationto
endometrial cancer risk.
In this multi-center study, there was a high degree of
standardization across study centers of recruitment and
blood collection protocols and questionnaire data.
Furthermore, all the hormone measurements were
made in one laboratory with samples from case patients
and their matched control subjects assayed at the same
time. The prospective design of our study minimizes
the risk of ‘reverse causation’ bias that may occur
when alterations in endogenous hormone levels are
induced by metabolic effects of an existing tumor, anti-
tumor treatments, psychological stress, or lifestyle
changes after cancer diagnosis.
The ﬁnding that obesity is associated with increased
endometrial risk in postmenopausal women is well
established (Kaaks et al. 2002, Vainio & Bianchini
2002), and the prevailing hypothesis is that this
association can be explained by increases in the
amount of bioavailable estrogens in the circulation
and the endometrial tissue (Kaaks et al. 2002). After
the menopause, when ovarian production of both
estrogen and progesterone ceases, the major source of
estrogen is via peripheral conversion, mostly within
adipose tissue, of androgens that continue being
produced by the adrenal glands and ovaries.
In addition, weight-related increases in insulin inhibit
the synthesis of SHBG (Plymate et al. 1988), a protein
that tightly binds estradiol and testosterone.
In consequence, increasing adiposity is associated
Table 3 Geometric means (95% conﬁdence interval) of steroid hormone levels for endometrial cancer case patients and control
subjects, by menopausal status at the time of blood donation
Premenopausal women Postmenopausal women
Hormone Case patients Control subjects Case patients Control subjects
SHBG (nmol/l) 48.4 (42.2–55.5) 51.0 (46.2–56.2) 42.6 (39.7–45.7) 47.9 (45.5–50.4)
†
DHEAS (mmol/l) 2.59 (2.19–3.06) 2.41 (2.13–2.72) 1.84 (1.66–2.05) 1.89 (1.75–2.04)
Androstenedione (nmol/l) 5.14 (4.65–5.69) 4.97 (4.62–5.34) 3.71 (3.49–3.95) 3.75 (3.58–3.92)
Testosterone (nmol/l) 1.39 (1.24–1.55) 1.36 (1.25–1.47) 1.32 (1.22–1.43) 1.20 (1.14–1.28)*
Free testosterone (pmol/l) 18.3 (15.7–21.2) 17.4 (15.6–19.4) 18.8 (17.2–20.7) 15.9 (14.9–17.0)
†
Estrone (pmol/l) 138 (130–148) 121 (116–127)
†
Estradiol (pmol/l) – – 98.8 (93.1–105) 89.1 (85.3–92.9)
‡
Free estradiol (pmol/l) – – 2.40 (2.24–2.58) 2.09 (1.98–2.19)
‡
*P!0.05,
†P!0.01,
‡P!0.001. Analysis based on 162 premenopausal women (55 case patients and 107 control subjects) and 566
postmenopausal women (192 case patients and 374 control subjects). Measurements were not taken for estrone, estradiol, or free
estradiol among premenopausal women. DHEAS, dehydroepiandrosterone sulfate; SHBG, sex hormone-binding globulin.
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www.endocrinology-journals.org 492with increasing blood concentrations of estrogen, and
with increasing fractions of estradiol (and also
testosterone) unbound to SHBG, that can freely diffuse
to target tissues. These well-known relationships of
adiposity with circulating levels of total and bioavail-
able estradiol were clearly seen in our data. Although
the association between BMI and endometrial cancer
risk in postmenopausal women was only moderately
weakened after an adjustment for free estradiol, the
corresponding c
2-value declined by half and since
hormone levels in single blood samples are only
moderately representative of true long-term hormone
levels (Potischman et al. 1994, Falk et al. 1997, Rinaldi
et al. 2001), adjustment by the true hormone level
would be expected to reduce the relative risk estimates
for BMI, and corresponding c
2, even more (Fletcher
et al. 1976). Residual confounding by hormone levels
could therefore explain most of the association
between obesity and endometrial cancer risk.
However, one cannot exclude the possibility that
obesity may, at least partly, inﬂuence endometrial
cancer risk via mechanisms that are unrelated to
bioavailable estrogen levels (e.g. that are related to
chronic hyperinsulinemia and reductions in endo-
metrial tissue concentrations of IGF-binding protein-1
(Kaaks et al. 2002) or to low adiponectin levels
(Cust et al. 2007) or inﬂammatory factors (Modugno
et al. 2005)).
Our study results also indicate that increasing
circulating levels of free testosterone and, to a lesser
extent, total testosterone are also associated with
increasing postmenopausal endometrial cancer risk.
Figure 1 Odds ratio (and their corresponding 95% conﬁdence intervals (CIs)) for endometrial cancer by serum levels of SHBG and
sexsteroids(intertiles)amongpostmenopausalwomen.Solidsquaresrepresent oddsratios(ORs),estimated byconditional logistic
regression, for tertiles of serum hormone concentrations (cut points based on the distribution of control subjects) and horizontal lines
represent 95% CIs. Analysis based on 192 case patients and 374 control subjects. Case patients and control subjects were matched
on EPIC (European Prospective Investigation into Cancer and Nutrition) recruitment center, age at blood donation, time of day at
blood donation, and fasting status. DHEAS, dehydroepiandrosterone sulfate.
1PtrendZP value for a test of linear trend across
categories basedon median hormonevalues forthe threetertiles.
2PtrendZP value for a testof linear trendbased on log-transformed
continuous variable.
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prospective study, which showed an association of risk
with total testosterone (Lukanova et al. 2004). Since in
this previous study, risk was also inversely related to
SHBG levels, it is likely that risk would also be
positively related to free testosterone levels, although
no direct estimates for free testosterone were provided.
Taken together, these results suggest that free
testosterone may be an important determinant of
endometrial cancer risk in postmenopausal women.
The magnitude of risk associated with free testosterone
was similar to that of the estrogens and because the
levels of sex hormones are positively correlated with
each other, it is difﬁcult to identify which single
hormone is most strongly associated with endometrial
cancer risk. However, unlike estrogens, testosterone
does not seem to have a direct stimulatory effect on
endometrial cell proliferation (Tuckerman et al. 2000).
Analyses with mutual adjustments between the
androgens (testosterone and free testosterone) and
estrogens (estrone, estradiol) suggest that, in this age
group, the association of endometrial cancer risk with
free testosterone levels could be a result of peripheral
conversion of these androgens into estradiol. In
contrast to previous prospective (Lukanova et al.
2004) and case–control studies (Austin et al. 1991,
Potischman et al. 1996), we found no evidence that
elevated levels of androgens of adrenal origin, such as
A-dione and DHEAS, were associated with risk.
Free testosterone levels used in the present analyses
were calculated on the basis of mass action law
equations, which have been previously validated
Figure 2 Odds ratio (and their corresponding 95% conﬁdence intervals (CIs)) for endometrial cancer by serum levels of SHBG and
sex steroids (in tertiles) among postmenopausal women after adjustment for BMI*. Solid squares represent odds ratios (ORs),
estimated by conditional logistic regression, for tertiles of serum hormone concentrations (cut points based on the distribution of
control subjects) and horizontal lines represent 95% CIs. Analysis based on 192 case patients and 374 control subjects. Case
patients and control subjects were matched on EPIC (European Prospective Investigation into Cancer and Nutrition) recruitment
center, age at blood donation, time of day at blood donation, and fasting status. DHEAS, dehydroepiandrosterone sulfate. *BMI
included as a continuous variable.
1PtrendZP value for a test of linear trend across categories based on median hormone values for
the three tertiles.
2PtrendZP value for a test of linear trend based on log transformed continuous variable.
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trations, by theoretical simulations and direct compari-
son with free testosterone measurements obtained by
an equilibrium dialysis method (Rinaldi et al. 2002).
Additional simulations in our laboratory have shown
that these same calculation methods will also provide
valid results for premenopausal women, provided that
their blood levels of testosterone, estradiol, SHBG,
and dihydrotestosterone are all within the normal
(non-pathological) range. A direct validation of
calculated versus directly measured values of free
testosterone in premenopausal women was published
by Vermeulen et al. (1999).
This prospective study is the ﬁrst to examine the
association between endogenous androgens and
endometrial cancer risk among women who were
premenopausal at blood donation. It has been
hypothesized that in premenopausal women,
whose circulating estradiol levels generally are
above a threshold of about 50 pg/ml (184 pmol/l),
endometrial cancer risk is not related to between-
subject differences in circulating estradiol levels,
but that low progesterone levels may be a more
important determinant of risk (Key & Pike 1988).
However, this is difﬁcult to examine directly in
large-scale epidemiologic studies because of the
marked cyclical variation in estradiol and pro-
gesterone levels in premenopausal women. Never-
theless, this hypothesis is consistent with the
epidemiologic observations of a higher endometrial
cancer risk among women with polycystic ovarian
syndrome, a condition characterized by obesity,
ovarian hyperandrogenism, anovulation, and pro-
gesterone deﬁciency (Hardiman et al. 2003). The
present study, however, showed no association
between obesity or circulating androgen levels
and endometrial cancer risk in women who were
premenopausal at blood donation, and which is
consistent with some, but not all previous data (all
from traditional case–control studies; Tornberg &
Carstensen 1994, Potischman et al.1 9 9 6 , Furberg
& Thune 2003). It has been suggested that the
increased risk associated with obesity in young
women is restricted to women with high levels of
BMI (Kaaks et al.2 0 0 2 ), and it is possible that
the low numbers of cases who were obese in this
study limited the power to detect a signiﬁcant
association.
A limitation of our study was the lack of data about
menopausal status at the time of endometrial cancer
diagnosis. However, the average follow-up time was
still relatively short (w3 years), and 71% of
endometrial cancer case patients had their tumors
detected !5 years after blood donation. Thus, for most
women who had gone through the menopause between
the time of blood donation and endometrial cancer
diagnosis, the time since menopause must have been
short and it is unlikely that risk would have changed
markedly during that time. Another potential limitation
is that the absolute concentrations of estradiol in
postmenopausal women in this study are relatively
high (geometric mean of 89 pmol/l in control
subjects), considering their true values are expected
to be !20 pmol/l. However, the steroid hormone
assays used in the present study have been validated
and showed very high correlations (O0.90) with
values obtained by an indirect immunoassay after
organic extraction and chromatographic pre-puriﬁ-
cation (Rinaldi et al. 2001), suggesting that the relative
ranking of women according to their estrogen level is
not affected using these assays. Finally, serum levels of
androgens and estrogens may be poor indicators of
total androgenic and estrogenic activities as they do not
reﬂect local conversion of adrenal precursors (such as
DHEA and DHEAS) into more active sex steroids in
target tissue (Labrie et al. 2003). The true relative risks
associated with the elevated serum and tissue concen-
trations of estrogens and testosterone therefore may
have been underestimated in our study.
In conclusion, this case–control study nested with a
prospective cohort provides strong evidence that
elevated levels of estrogens (estrone, estradiol, and
free estradiol) and free testosterone are associated with
increased endometrial cancer risk in postmenopausal
women. By contrast, androgens of predominantly
adrenal origin were not related to risk in postmeno-
pausal women. The positive association between BMI
and endometrial cancer risk in postmenopausal women
is most probably explained by weight-related increases
in estrogen levels, although alternative (or comp-
lementary) physiological mechanisms cannot be ruled
out. In premenopausal women, serum sex hormone
concentrations were not associated with endometrial
cancer risk, although there were too few numbers to
draw ﬁrm conclusions.
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